Biological therapy for lupus nephritis-tribulations and trials.

Nature Reviews. Rheumatology
Rona M SmithDavid R W Jayne

Abstract

Several new targeted biologic agents for treating lupus nephritis are on the horizon; however, it is important to determine the circumstances in which they should be used, and how to optimally combine these agents with current or other new therapies. Conventional immunosuppressive therapy has transformed survival in lupus nephritis, but its use is associated with considerable toxic effects and suboptimal efficacy. There is a clear need for new therapeutic agents that overcome these issues, and biologic agents offer exciting opportunities. B cells, T cells, cytokines and complement are potential targets for these therapies. It is anticipated that the role of B-cell depletion in lupus nephritis will be clarified and that other biologic agents will be developed. The complexities of clinical trials in lupus nephritis have impeded the demonstration of the efficacy of new agents, but if these difficulties can be overcome, there is a real chance that outcomes in lupus nephritis will improve.

References

Feb 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·D I Daikh, D Wofsy
Feb 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Emily C BaechlerTimothy W Behrens
Mar 19, 2003·The Journal of Experimental Medicine·Lynda BennettVirginia Pascual
Sep 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai Weng, Ronald Levy
Sep 8, 2004·Autoimmunity Reviews·Andrea T BorchersM Eric Gershwin
May 17, 2007·Annals of the Rheumatic Diseases·G BertsiasUNKNOWN Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
Oct 9, 2007·Annals of the Rheumatic Diseases·P I SidiropoulosD T Boumpas
Oct 19, 2007·Seminars in Immunopathology·Menna R Clatworthy, Kenneth G C Smith
Feb 12, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·D D BloomS J Knechtle
Jun 6, 2008·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Robert G Lahita
Aug 1, 2008·Arthritis and Rheumatism·Mario H CardielUNKNOWN LJP 394-90-09 Investigator Consortium
Jul 21, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ruth PepperTom Cairns
Jun 4, 2010·Nature Reviews. Rheumatology·Iñaki Sanz, F Eun-Hyung Lee

❮ Previous
Next ❯

Citations

Mar 16, 2011·Journal of Biomedicine & Biotechnology·Daniel PerryLaurence Morel
Jun 3, 2014·BMC Musculoskeletal Disorders·Helena MarcoDavid R W Jayne
Nov 26, 2014·Nature Reviews. Nephrology·Tak Mao Chan
Sep 3, 2011·The Journal of Rheumatology·Mikkel FaurschouSøren Jacobsen
May 3, 2011·Nature Reviews. Drug Discovery·Iñaki SanzPeter Kirkpatrick
Sep 15, 2017·Nature Reviews. Rheumatology·Michaela SeelingFalk Nimmerjahn
Jun 28, 2011·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Wako Yumura
Jun 17, 2020·Proceedings of the National Academy of Sciences of the United States of America·Chenzhi JingMenna R Clatworthy
Jan 28, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Tracy Y ZhuEdmund K Li
Oct 2, 2015·Oncotarget·Lynn M Corcoran, Stephen L Nutt

❮ Previous
Next ❯

Related Concepts

Related Feeds

B cell Differentiation

Depending on the signal received through the B cell receptor and other receptors, B cells differentiate into follicular or marginal zone B cells. Here is the latest research pertaining to this differentiation process.